Aastrom's adult stem cell tech shows promise in US bone fracture trial
This article was originally published in Clinica
The use of Aastrom Biosciences' adult stem cell-based technology as a treatment for non-union long bone fractures appears to be safe and effective, according to early results from an ongoing phase II US trial.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.